Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
ProFound Therapeutics Partners with Novartis in $775M Cardiovascular Drug Discovery Deal
ProFound Therapeutics announced a four-year strategic collaboration with Novartis to discover novel cardiovascular therapeutics using its ProFoundry Platform to mine the expanded human proteome.
Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen
Vor Bio acquired exclusive global rights (excluding Greater China) to develop and commercialize telitacicept, a dual-target fusion protein approved in China for multiple autoimmune diseases including generalized myasthenia gravis.
Biogen Advances Salanersen to Phase 3 Studies for Spinal Muscular Atrophy After Promising Results
Biogen's salanersen (BIIB115/ION306) demonstrated substantial slowing of neurodegeneration and clinically meaningful motor function improvements in children with spinal muscular atrophy previously treated with gene therapy.
TOLREMO Therapeutics Strengthens Leadership with Key Appointments as TT125-802 Shows Clinical Promise
TOLREMO therapeutics has appointed Alessandra Cesano, MD, PhD, to its Board of Directors and named Florian D. Vogl, MD, PhD, as Chief Medical Officer to strengthen leadership capabilities.
Maxion Therapeutics Strengthens Leadership with Appointment of Dr. Stefan Härtle as Chief Development Officer
Maxion Therapeutics has appointed Dr. Stefan Härtle as Chief Development Officer, bringing nearly 20 years of pharmaceutical R&D experience to advance the company's KnotBody® platform into clinical trials.
Comprehensive Analysis Reveals 943 Autoimmune Collaboration and Licensing Deals Across 30 Diseases from 2016-2025
A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.
Bristol Myers Squibb Acquires Novel Prostate Cancer Radiopharmaceutical for $1.35 Billion
Bristol Myers Squibb agreed to pay $350 million upfront to Philochem for worldwide rights to OncoACP3, an experimental radiopharmaceutical targeting the ACP3 protein for prostate cancer diagnosis and treatment.
Zigakibart Shows Sustained 60% Proteinuria Reduction in 100-Week IgA Nephropathy Study
Zigakibart, an investigational anti-APRIL monoclonal antibody, demonstrated sustained efficacy with 60% proteinuria reduction from baseline at 100 weeks in IgA nephropathy patients.
Leon-nanodrugs Appoints Dr. Wolfgang Hofmann as CEO to Drive Nanoparticle Manufacturing Technology Commercialization
Munich-based leon-nanodrugs GmbH has appointed Dr. Wolfgang Hofmann as CEO to lead the company's transition from development to commercialization of its FR-JET® nanoparticle manufacturing technology.
Essential Thrombocythemia Market Set for Significant Growth as Novel Therapies Enter Pipeline
Essential thrombocythemia affects approximately 167,000 individuals in the US as of 2024, with 75% of cases linked to JAK2 gene mutations and only one approved therapy currently available in Europe.